Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418976 | 0.92 | JAK3 (0.44) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL26917154 | 0.92 | KMT2A (0.42) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL2425813 | 0.91 | JAK3 (0.47) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| Bromide SCHEMBL6990879 | 0.88 | HRH3 (0.47) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL6988822 | 0.85 | HTR1F (0.41) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL26916539 | 0.80 | KMT2A (0.40) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL31229951 | 0.77 | NPC1 (0.47) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| Cyclopropane Carboxylic Acid SCHEMBL2962866 | 0.77 | KMT2A (0.40) | KMT2ARAB9ANPC1JAK3LMNA | |
| SCHEMBL1705485 | 0.76 | NPC1 (0.40) | KMT2ARAB9ANPC1SMN1; SMN2GLA | |
| SCHEMBL6994122 | 0.76 | MEN1 (0.52) | KMT2ASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1066237-A2 | PROCESSES FOR PREPARING INTERMEDIATES | AVENTIS CROPSCIENCE S.A. (FR) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048851-A2 | PROCESSES FOR PREPARING INTERMEDIATES | AVENTIS CROPSCIENCE S.A. (FR) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | KMT2A 2250/4885RAB9A 2869/4885NPC1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.